Market & Forensics Analyst, Beat the Street

Nimish Maheshwari

Nimish Maheshwari, an independent analyst and co-founder of Beat The Street, is an investing platform garnering more than 1,00,000+ followers across social media. 
His deep insights and forensic analysis have been featured in some of India's most prominent publications, including the Economic Times, The Morning Context, The Ken,  Dalal Street Investment Journal, Moneylife by Sucheta Dalal, and TheCore.in.
He has a keen eye for identifying red flags in Indian listed companies and has identified exclusive red flags earlier in Adani, Vedanta, Nykaa, Gland Pharma, Brightcom Group etc.

Market & Forensics Analyst

Coromandel's Strategic Play for NACL Industries: Bottom of the Agrochem Cycle Bargain?

Bajaj Finserv Acquires Full Control of Bajaj Allianz Life & General Insurance

Manappuram Finance: Bain Capital’s Entry Signals a New Chapter, But Challenges Remain

Event Driven: Shankara Building Products, A Demerger Play

Event Driven: Vedanta Ltd: A Story of Wealth Creation Through Demerger

Event Driven: UltraTech’s Bold Foray into Wires & Cables 80,000+ Cr Market

Event Driven: KKR Acquired Controlling Stake in HealthCare Global

The Beat Ideas: Blue Jet Healthcare- Rising CDMO Player

Beat the Street

Beat The Street was founded by Nimish Maheshwari and Sudarshan Bhandari, both of whom are Chartered Accountants by Profession, known for their expert analysis in the fields of Business, Sectoral analysis, and Corporate governance.

With a strong social media presence of 45,000+ Subscribers across various platforms, they are considered trusted voices in the industry. Their insights and analysis have been featured in some of India’s most prominent publications, including the Economic Times, Dalal Street Investment Journal, The Morning Context, and The Ken.

Their analysis on Bankrupt & Insolvent companies has been instrumental in saving investors from significant losses. They have a keen eye for identifying red flags and has identified exclusive redflags earlier in Vedanta, Nykaa, Dhani Services, Adani and many more.

Read Business Not Stock Prices

Event-Driven

Sun Pharmaceutical Industries / Event-Driven

<ul>
<li>
<a href="https://www.smartkarma.com/entities/sun-pharmaceutical-industries-limited" target="_blank" data-smartkarma-citation="entities:98:1" rel="noopener">Sun Pharmaceutical Industries (SUNP IN)</a> is set to acquire Checkpoint Therapeutics for $355 million, enhancing its onco-dermatology portfolio with UNLOXCYT™, an FDA-approved treatment.</li>
<li>This strategic move provides Sun Pharma with immediate access to the U.S. market and the potential for global expansion, especially in the PD-1 inhibitor space.</li>
<li>The acquisition promises revenue growth and synergistic opportunities, although regulatory approvals and successful integration are crucial for realizing its full potential.</li>
</ul>



Sun Pharmaceutical Industries (SUNP IN) is set to acquire Checkpoint Therapeutics for $355 million, enhancing its onco-dermatology portfolio with UNLOXCYT™, an FDA-approved treatment.
This strategic move provides Sun Pharma with immediate access to the U.S. market and the potential for global expansion, especially in the PD-1 inhibitor space.
The acquisition promises revenue growth and synergistic opportunities, although regulatory approvals and successful integration are crucial for realizing its full potential.


How Acquiring Checkpoint Therapeutics Inc Adds Value to Sun Pharma?